Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Ernie Hudson is tempting his fans with a sexy new partnership.   The “Ghostbusters” actor is joining forces with ...

The health ministry has secured over 268,000 updated vaccines for this year’s and next year’s autumn and winter seasons, with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.